Imatinib (IM), an oral 2-phenylaminopyrimidine derivative that works as a selective inhibitor against mutant forms of type III tyrosine kinases such as KIT, PDGFRA, and BCR/ABL, has significantly improved the clinical outcome of patients with advanced GIST. Here, KIT is linked to gastrointestinal stromal tumor.